SCHEMBL24904264

SCHEMBL24904264

O=C1NC(=S)N/C1=C\c1ccc2nccnc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.64
CLK1 P49759 2/20 0.64
CSNK2B P67870 2/20 0.64
CSNK2A1 P68400 2/20 0.64
DYRK1A Q13627 2/20 0.64
DYRK2 Q92630 2/20 0.64
DYRK1B Q9Y463 2/20 0.64
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
IDH1 O75874 3/20 0.56
PIK3CD O00329 1/20 0.56
NPC1 O15118 1/20 0.56
MAOB P27338 1/20 0.56
PIK3CA P42336 1/20 0.56
PIK3CB P42338 1/20 0.56
MTOR P42345 1/20 0.56
PIK3CG P48736 1/20 0.56
RAB9A P51151 1/20 0.56
CISD1 Q9NZ45 1/20 0.56
MAPT P10636 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30363450 1.00 CSNK2A2 (0.64) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL26092915 0.83 MEN1 (0.67) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL24904485 0.83 MEN1 (0.67) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL23510560 0.79 CSNK2A2 (0.56) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL30494166 0.79 CSNK2A2 (0.56) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL26094685 0.79 MEN1 (0.60) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL23499923 0.78 CLK1 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL30145013 0.78 CLK1 (1.00) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL23510685 0.78 DYRK1A (0.81) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL26094203 0.78 CLK1 (0.59) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340538-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 US disclosed
WO-2023072969-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 WO disclosed
WO-2023072969-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 WO disclosed
EP-4173674-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 EP disclosed
EP-4173674-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 EP disclosed
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 CSNK2A2 394/4885CLK1 2884/4885CSNK2B 246/4885
US-20250340538-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 CSNK2A2 107/4885CLK1 1/4885CSNK2B 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.